Sanara MedTech Inc. (SMTI) is a publicly traded company in the Healthcare — Medical - Instruments & Supplies industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities.
Analysis Summary
Sanara MedTech Inc. reported revenue of $103.1M in the most recent fiscal year, growing at a 5-year CAGR of 45.9%.
Trailing-twelve-month margins: gross margin 91.3%, operating margin 9.4%, net margin -29.2%.
At the current price of $35.10, SMTI has negative trailing earnings (P/E not meaningful) and an ROE of -473.55%. Market capitalisation stands at $323M.
Balance sheet quality for SMTI: current ratio of 1.8, net debt of $31.6M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $35.10 |
| Market Cap | $323M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 38.51 |
| EV / EBITDA | 37.56 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -473.55% |
| Return on Invested Capital | 18.02% |
| Return on Assets | -46.30% |
| Gross Margin | 91.33% |
| Operating Margin | 9.36% |
| Net Margin | -29.15% |
Financial Health
| Debt / Equity | 6.11 |
| Current Ratio | 2.58 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| SMTI | Sanara MedTech Inc. | $322M | 38.51 | -473.6% | |
| 0R29.L | Intuitive Surgical, Inc. | $131.0B | 71.41 | 11.44 | 16.0% |
| ISRG | Intuitive Surgical, Inc. | $130.4B | 43.34 | 7.48 | 17.8% |
| 0R19.L | Becton, Dickinson and Company | $50.3B | |||
| BDX | Becton, Dickinson and Company | $50.0B | 55.98 | 2.09 | 3.8% |
| RMD | ResMed Inc. | $33.1B | 21.86 | 5.02 | 23.9% |
| 0KW4.L | ResMed Inc. | $32.5B | |||
| MDLN | Medline Inc. | $27.6B | 37.35 | 2.38 | 5.4% |
Price Performance
| 1 month | +2.38% |
| 3 months | +59.38% |
| Year-to-date | +50.30% |
| 1 year | +1.31% |
| 3 years | +1.14% |
52-Week Range
| 52-week High | $35.27 |
| 52-week Low | $16.05 |
| Avg Volume (90d) | 195K |
Dividend History
| Date | Amount | Yield |
|---|---|---|
| 2027-07-29 | $33.0000 | 376.07% |
Related companies: HITI · LFMD · NEO · OMI · SGHT · STXS · TBRG
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of SMTI: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks